Stocklemon reports on GeneMax (OTC BB:GMXX)
| stock ticker: GMXX | ||
 |
      |
|
When Bad Things Happen To Good People
Shares Outstanding: 15 million
Market Cap: $83 million
Revenues Since Inception: 0
Cash in Bank: $180,000
GeneMax (the “Company”) is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.